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Abstract
Many factors affect the success of companies in the medical technology (MedTech) industry, a major contributor to Ireland’s and 
Europe’s economy. Open Innovation (OI) is a well documented innovation strategy which sees companies utilize outside 
knowledge to enhance their capabilities or allow outside partners or independent actors to share or buy their unused intellectual 
property. There are many advantages to be gained from using open innovation including increased revenues and up-to-date 
product ranges. A survey was administered in order to gain an understanding of key aspects of OI as practiced in the Galway 
MedTech cluster in Ireland. These included OI Practices, OI Drivers, and OI Barriers. The survey was based on a similar survey 
administered in a Danish-Swedish MedTech cluster called Medicon Valley (MV). It was found that in the Galway MedTech 
cluster significant emphasis was placed on R&D and also production in the practice of OI. Outsourcing of R&D was found to be 
a frequently used OI strategy, though there was a distinct reluctance to create spin-off companies which reflected a desire to 
retain exclusive access to propriety knowledge. The main Drivers of OI were found to be Capacity, Control and Market. The 
main Barriers to OI were found to be the availability of Finance, Quality of Partners and Idea Management. The partners most 
frequently used within the cluster were Knowledge Institutions and Consultants or Engineering Firms. Within the MV cluster 
greater emphasis was placed on R&D as an OI practice. In general, a similar profile with respect to OI Practices and Barriers as 
that observed in the Galway cluster was observed in the MV cluster. There was however differences in the Drivers of OI 
particularly with respect to Outsourcing of R&D. One possible explanation is that there were a greater proportion of micro start-
ups in the MV cluster than in the Galway MedTech cluster.
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1. Introduction
1.1. Medical technology
“Medical Technology (MedTech) are defined as medical devices, in vitro diagnostics, imaging equipment and e-
health solutions used to diagnose, monitor, assess predispositions and treat patients suffering from a wide range of 
conditions” [1]. MedTech innovation results in people living healthier and for longer, aids in the creation of more 
efficient healthcare systems and is a substantial catalyst for economic growth [2].
Nomenclature
MedTech Medical Technology
MV Medicon Valley
EI Enterprise Ireland
OI Open Innovation
IMDA Irish Medical Device Association
SME Small to Medium Enterprise
MNC Multi-National Corporation
IDA Industrial Development Authority (Ireland)
1.2. Medical technology industry in Ireland
Ireland is home to one of the leading clusters in Europe’s medical (MedTech) sector. There are 250 MedTech 
companies in Ireland, employing 25,000 people and exporting 7.9 billion Euro worth of product annually. This 
represents 8.5% of Ireland’s total merchandise exports. While 50% of the companies are indigenous, there is also a 
significant presence from the top MedTech sector companies in Ireland with 17 of the top 25 companies based there 
[3]. Galway is considered to contain one of Europe’s premier clusters of medical device companies [4]. The 
companies involved are a mixture of Small to Medium Enterprises (SMEs) and large multi-national corporations 
(MNCs). Thirty one percent of medical device companies in Ireland are located within the Galway MedTech cluster 
and the region has been identified as the principle center of activity for both indigenous start-ups and international 
medical device companies.
The MedTech industry in Ireland is shifting from a predominantly manufacturing environment to one more 
driven by R&D and innovation. In order to remain competitive and be successful in this area, collaboration is 
necessary between several parties including the manufacturers, clinicians, research institutes and the government 
[3]. Successful collaboration leading to innovation can be achieved through the implementation of Open Innovation 
(OI) practices. However, in order to achieve this Drivers of OI need to be identified and embraced and OI Barriers 
need to be overcome.
1.3. Open Innovation (OI)
Open Innovation can be defined as, “The use of single purposive inflows and outflows of knowledge to 
accelerate internal innovation and expand the markets for external use of innovation respectively” [5]. There can be 
a wide variety of actors involved in OI, and they typically include customers, universities, suppliers, competitors, 
and users [6]. Organizational boundaries between the environment and firm are porous in OI processes.  There are 
four key elements needed to fully implement OI: Development of Networks, Consolidating Knowledge Exchange, 
Protection Mechanisms for Intellectual Property and Supportive Business Models. The primary Drivers of OI 
include: Unique Market Opportunities, Changes in Technology and Shorter Product Life Cycles, Turbulent Business 
Environments, Movement of Market Labor and the Need to Generate Revenue [7]. Barriers to OI are categorized in 
the literature as: Intellectual Property, Internal Barriers such as Resistance to Change, External Barriers including 
Government Support, and Legislative and Regulatory Concerns, Business Model, Managerial Challenges, Cost and 
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the existence of Appropriate Networks. Open Innovation is viewed as a key driver of the development of the 
MedTech sector in Ireland and more specifically the Galway cluster.  In order to understand how and the extent to 
which OI is situated within the cluster a survey based on a similar OI survey administered in the Medicon Valley 
cluster in Denmark/Sweden was undertaken [8]. The results from the Galway MedTech cluster were compared to 
those obtained in the Medicon Valley cluster, however only a small number of these of these are reported in this 
paper.
2. Objectives
The main aim of the study reported in this paper was to identify the extent of OI practices in the Galway 
MedTech cluster and the drivers and barriers in relation to the adoption of OI within it. A secondary aim was to 
compare the results to a previous survey conducted within the Medicon Valley Life Science cluster which spans 
Denmark and Sweden [8]. The results of the study would enable the Galway cluster to benchmark its activities 
against best practice and where appropriate to modify its operating behaviour in order to enhance its OI practices.
2.1. Description of clusters
Galway is considered to contain one of Europe’s premier clusters of medical device companies [4]. According to 
the Irish Medical Device Association (IMDA) [3], there are approximately 50 companies involved in the MedTech
field in the Galway Cluster. The companies are a mixture of SMEs and MNCs and represent a combination of 50% 
indigenous and 50% international organizations. These are related to the fields of diagnostics hospital and/or 
homecare products, vascular, contract research, connected health and service [3]. The Galway Cluster is home to 
two private hospitals, a public hospital group and two third level institutions.
Medicon Valley (MV) is a cluster situated on the island of Zeeland in Denmark and the Swedish Skane region. 
Medicon Valley Alliance is a body which endeavors to ensure collaboration between life science companies, 
clinicians and academic researchers who are its members and is one of the largest such clusters in Europe. It helps 
businesses to find the right partners or investment opportunities, provides location services, and performs 
benchmarking analysis of different locations globally. Local and international investment of capital ensures 
continued success of the companies. In 2011, it was reported that there were in excess of 300 Life Science 
Companies, 32 Hospitals and 12 Universities within the cluster [9].
3. Methodology
3.1. Survey tool
The survey tool administered in the Medicon Valley (MV) Life Science cluster study was utilised in the current 
study [8]. Where necessary the language of some questions was modified for application to the Galway region and 
those questions that were found to be not relevant were deleted. The modified survey was piloted to review layout, 
comprehension, spelling and completion time and it was fine-tuned based on the feedback obtained. The survey 
consisted of 16 questions and was divided into the following sections:
x Basic Company Details: Fundamental information on the company including size, length of time in existence and 
their degree of involvement in R&D.
x OI Practices: Types of OI practices used the extent to which they are utilised, importance to the company, and the 
manner and extent of their linkages to continuous improvement.
x Drivers of OI in relation to innovation practices.
x The Barriers to OI in relation to different innovation strategies.
x The networking activities performed both inside and outside the MedTech cluster.
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The survey was accompanied by an information sheet in which the background to the study and its objectives 
were presented. Clear instructions for completion of the survey were provided and anonymity and confidentiality 
was assured. It was explained that it was envisaged that the general findings of the work would be published but that 
no individual or company would be identified or identifiable in any publication.
3.2. Survey population and administration
MedTech companies in the regions were identified through contact with statutory bodies, government
development agencies, and representative bodies. These included: The Industrial development Authority (IDA); 
Enterprise Ireland; and The Irish medical Device Association (IMDA). A survey population of 43 companies was 
identified and potential individual respondents in 25 of these were contacted directly either by voice or email. For 
the remainder the general company email was used for distribution of the survey.
The survey was administered on-line using KwickSurveys.com. An email with a direct link to the survey was 
sent to the 25 individual respondents previously identified and also to the general email address of the remaining 18 
companies for distribution to the relevant professional responsible for innovation. An initial period of 10 days was 
given to complete the survey. After this period, a follow-up phone call was made to those companies who hadn’t 
responded to remind them that their response was required. In order to take account of non-response bias, a non-
response follow-up was performed. This involved contacting the non-responders by phone and asking them to 
answer a number of short questions. Similarities between the answers of the non-respondents and the survey 
population were noted and supported the position that the survey population was not biased.
4. Results
4.1. Company information
x Response Rate: Thirty one companies out of 43 responded giving a response rate of 72%
x Field of Business: Twenty six companies selected MedTech, while two others selected Biotech & Medtech and 
Pharmaceutical & Medtech respectively. Three companies indicated that their field of business was exclusively 
Biotech or Pharmaceutical and were eliminated from the study.
x Company Activity: Seventeen companies reported being involved in production and R&D, 9 in R&D only and 1 
in production only. One respondent reported being involved in validation and testing only.
x Importance of Galway as a Location: Galway as a cluster of MedTech industries was rated as a Determining 
Factor in company location by 5 companies, Very Important by 10 companies and Important by 8 companies. 
The remaining 5 companies reported that it was Not Important.
4.2. Open Innovation practices
x Relevance of Open Innovation: All companies reported that OI was applicable to their organisation. Two of these 
reported that it was not important. Five others reported being neutral regarding its importance. Of the remaining 
21 companies, 15 considered it important and 6 deemed it very important.
x Importance of Continuous Innovation: Five respondents reported that they were neutral with respect to the 
importance of Continuous Innovation. Seventeen considered it to be important while the remaining 6 considered 
it to be very important.
x Open innovation Practices: Respondents selected the Innovation Practices that they used from a list provided. An 
option was also provided where it was possible to indicate a practice not included in the list. Respondents were 
also asked to report the extent to which their engagement with these practices had increased or otherwise in the 
past five years. The results are reported in Table 1 below:
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Table 1. Innovation practices.
Innovation Practice (IP) Used By > Engagement with 
IP over past 5 Yrs
IP1 Outsourcing of R&D 14 6
IP2 Creation of Spin-offs 9 2
IP3 Participate in New or Existing Business via Joint or 
Capital Venture
14 7
IP4 Systematic Search for Cooperative Partners in the 
Galway MedTech Cluster
14 5
IP5 Licensing Patents to other Parties 7 1
IP6 Licensing Patents from other Parties 9 1
Other 1 1
4.3. Open Innovation drivers and barriers
Respondents were asked to align the OI Practices identified above with a list of OI Drivers. The results are 
reported in Table 2. below:
Table 2. Open innovation drivers of innovation practices.
OI Drivers IP1 IP2 IP3 IP4 IP5 IP6 Total
Control 6 3 3 7 - 1 20
Focus 5 2 3 8 - - 18
Renewal 3 - 4 8 1 1 17
Knowledge 7 - 2 9 - 2 20
Costs 8 - 3 5 1 2 19
Capacity 8 1 6 5 - - 20
Market 6 1 4 7 1 1 20
Utilisation 4 1 2 8 - 3 18
Policy 5 2 2 6 1 - 16
Motivation 3 4 1 8 - - 16
Other - - - 1 - - 1
Note: Respondents could select more than one OID for each IP
Respondents were asked to align the OI Practices above with a list of OI Barriers. The results are reported below
in Table 3:
Table 3. Open innovation barriers to innovation practices.
OI Barriers IP1 IP2 IP3 IP4 IP5 IP6 Total
Administration 6 3 - 4 - 1 14
Finance 4 4 3 3 - 2 16
Knowledge 4 2 3 3 3 - 15
Marketing 2 - 6 5 - - 13
Organisation / Culture - 2 5 5 - - 12
Resources 4 4 3 3 - 1 15
Property Rights 2 2 1 3 1 4 13
Quality of Partners 6 - 5 2 - 2 15
User Acceptance 4 - 4 3 2 - 13
Customer Demand 5 - 3 5 - - 13
Competent Employees 3 1 4 1 - - 9
Commitment 3 2 4 4 - 1 14
Idea Management 5 2 2 4 1 1 15
Other - - 1 1 - 2
Note: Respondent could select more than one OIB for each IP
4.4. Networking
Respondents were asked to indicate the category of partner within the Galway MedTech Cluster they collaborate 
with from a list provided. They were also asked to identify the category of external partner they interact with from 
outside the Galway MedTech Cluster.
508   Bridget McCormack et al. /  Procedia Manufacturing  3 ( 2015 )  503 – 509 
Table 4. Internal and External Collaboration.
Parties Internal to MedTech Cluster                  Parties External to MedTech Cluster
Competitors 2 Competitors 4
Knowledge Institutions 20 Knowledge Institutions 18
Consultants or Engineering Firms 14 Consultants or Engineering Firms 16
Suppliers 19 Suppliers 18
Customers 13 Customers 14
Hospitals 13 Hospitals 12
Patient Associations 1 Patient Associations 12
Financiers linked to Cluster 10 Financiers external to Cluster 12
Other non-competitive Companies 10 Other external non-competitive Companies 14
5. Comparison with the Medicon Valley (MV) cluster [8]
5.1. Company basics
Despite the size of the MV cluster (230 companies) there was only a 12% response rate to the survey. In contrast 
a response rate of 65% was obtained in the Galway cluster. The main areas of activity in both clusters were reported 
to be production and R&D; however a higher percentage of companies in the MV cluster (64%) concentrated on 
R&D only when compared to the Galway Cluster (32%). An explanation for this could be that the majority of the 
existing companies in the Galway cluster may be further along the innovation cycle than some of the companies in 
the MV cluster. In order to sustain open innovation in the Galway cluster, more start-ups should be encouraged. 
Given the extent of the R&D activity reported, it was surprising to find that a minority of the companies in the MV 
cluster (7%) viewed their geographical location as very important. In the Galway case this figure was 36%.
5.2. Open Innovation practices
Slightly more companies in the Galway cluster reported that OI was relevant to their activities than in the MV 
cluster, (64% versus 72%). This could be possibly be explained by the length of time the respective companies were 
engaged in product or process development. In both cases nearly 90% of companies reported that they regarded 
continuous innovation as an important strategy for them. There was a positive relationship between the size of a 
company and the significance they attached to continuous innovation. 
The most popular OI strategies reported as being employed in both clusters were similar: Outsourcing of R&D; 
Participation in new or existing business via joint or capital venture; and Systematic look for partners. Respondents 
from the MV cluster reported licensing more patents from others than the Galway cluster. In the case of the MV 
cluster this is reported as relating to the Micro size of a number of the companies, while the maturity and size of 
some of the Galway cluster companies could explain the reported licensing of patents to others.
5.3. Drivers of and barriers to Open Innovation
The main driver of OI in both clusters was Knowledge while Cost was also considered as equally important in the 
MV area. Capacity, Control and Market were reported as being equally important in the Galway cluster.
Access to Finance was reported as the main barrier to OI in the Galway cluster. Knowledge, Resources, Quality 
of Partners and Idea Management were also seen as potential obstacles when attempting to engage in OI practices, 
whereas in the MV cluster IP Rights, Finance and Knowledge were found to be the key barriers to OI. Significant 
barriers were reported with regard to Outsourcing of R&D, in particular Administration, Quality of Partners and 
Idea Management. These reflect the difficulties associated with finding a business partner with suitable capabilities
[10].
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5.4. Networking
Networking was reported as being very important in both clusters whether internal or external to the particular 
cluster (see Table 4.) The key networking partners in the Galway cluster were Knowledge Institutions, Consulting or 
Engineering Firms and Suppliers. Similarly the MV cluster reported the same collaborators; however Hospitals were 
ranked higher in the order than Suppliers. This may reflect the need of the higher number of MV start-up companies 
to be closer to users at the early stage of the innovation cycle. In the Galway case companies may require greater 
interaction with suppliers due to the greater maturity in some of their activities.
6. Conclusions
The main question addressed in this paper was the extent of OI practices in the Galway Medtech cluster. A 
modified survey based on an earlier survey administered to the MV cluster in Sweden / Denmark was used to 
determine this. The results of the Galway cluster survey were compared to those from the MV survey. In general 
both clusters use the same OI Practices and encounter similar OI Barriers, e.g. Finance, Knowledge and Quality of 
Partners. However, differences in the Drivers of OI were reported. In particular, Outsourcing of R&D was driven by 
Cost in the Galway cluster and Capacity in the MV cluster. This is explained by the micro size of some of the 
companies in the MV cluster and the level of maturity of some of the companies in the Galway cluster.
It can be concluded that the MedTech cluster in Galway is engaging in OI in a most prolific manner. The results 
of the study should enable participants to become aware of the trends in OI and benefit them through reflection on 
their own practices
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